For instance, calcium/calmodulin-dependent kinase kinase 2 (CAMKK2) has been identified as one of the targets of the AR in both androgen-sensitive and castrate-resistant prostate cancer cell lines since the AR was recruited to the promoter of CAMKK2 in both stages of disease [9,43,44]. This evidence concerns the gene CAMKK2 and prostate carcinoma.